Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Drug Topics to discuss which indications patients typically gravitate toward for the use of GLP-1 medications.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed the common trends in GLP-1 use she’s seen amongst her patients as well as her extensive experience working with this medication class.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed her experience when beginning to counsel patients using GLP-1 medications.

Recently, the FDA alerted users of missed notifications for continuous glucose monitoring devices and Bluetooth smartphone compatibility.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.